Fulcrum Therapeutics Stock Cash And Equivalents
| FULC Stock | USD 3.15 0.13 4.30% |
Fulcrum Therapeutics fundamentals help investors to digest information that contributes to Fulcrum Therapeutics' financial success or failures. It also enables traders to predict the movement of Fulcrum Stock. The fundamental analysis module provides a way to measure Fulcrum Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Fulcrum Therapeutics stock.
Fulcrum |
Fulcrum Therapeutics Company Cash And Equivalents Analysis
Fulcrum Therapeutics' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Fulcrum Therapeutics Cash And Equivalents | 221.79 M |
Most of Fulcrum Therapeutics' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Fulcrum Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, Fulcrum Therapeutics has 221.79 M in Cash And Equivalents. This is 72.98% lower than that of the Pharmaceuticals sector and 50.4% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 91.79% higher than that of the company.
Fulcrum Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Fulcrum Therapeutics' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Fulcrum Therapeutics could also be used in its relative valuation, which is a method of valuing Fulcrum Therapeutics by comparing valuation metrics of similar companies.Fulcrum Therapeutics is currently under evaluation in cash and equivalents category among its peers.
Fulcrum Fundamentals
| Return On Equity | -0.0407 | ||||
| Return On Asset | -0.0478 | ||||
| Profit Margin | (0.12) % | ||||
| Operating Margin | (0.25) % | ||||
| Current Valuation | (61.82 M) | ||||
| Shares Outstanding | 53.98 M | ||||
| Shares Owned By Insiders | 1.87 % | ||||
| Shares Owned By Institutions | 97.17 % | ||||
| Number Of Shares Shorted | 4.44 M | ||||
| Price To Earning | (1.99) X | ||||
| Price To Book | 0.70 X | ||||
| Price To Sales | 2.13 X | ||||
| Revenue | 80 M | ||||
| Gross Profit | 16.61 M | ||||
| EBITDA | (18.24 M) | ||||
| Net Income | (9.72 M) | ||||
| Cash And Equivalents | 221.79 M | ||||
| Cash Per Share | 4.26 X | ||||
| Total Debt | 17.68 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 15.49 X | ||||
| Book Value Per Share | 4.50 X | ||||
| Cash Flow From Operations | (2.22 M) | ||||
| Short Ratio | 12.91 X | ||||
| Earnings Per Share | (0.16) X | ||||
| Price To Earnings To Growth | (0.45) X | ||||
| Target Price | 5.67 | ||||
| Number Of Employees | 45 | ||||
| Beta | 2.19 | ||||
| Market Capitalization | 170.03 M | ||||
| Total Asset | 260.72 M | ||||
| Retained Earnings | (519.4 M) | ||||
| Working Capital | 238.88 M | ||||
| Current Asset | 22.54 M | ||||
| Current Liabilities | 3.5 M | ||||
| Net Asset | 260.72 M |
About Fulcrum Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Fulcrum Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fulcrum Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fulcrum Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Fulcrum Therapeutics Piotroski F Score and Fulcrum Therapeutics Altman Z Score analysis. For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulcrum Therapeutics. If investors know Fulcrum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulcrum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Fulcrum Therapeutics is measured differently than its book value, which is the value of Fulcrum that is recorded on the company's balance sheet. Investors also form their own opinion of Fulcrum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fulcrum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulcrum Therapeutics' market value can be influenced by many factors that don't directly affect Fulcrum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulcrum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulcrum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulcrum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.